New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Cancer accounted for nearly 10 million deaths in 2020 – almost one in every six deaths globally – according to the World Health Organization.

Rigel Pharmaceuticals has enrolled the first patient in a Phase I trial to evaluate fostamatinib as a treatment for sickle ...

Researchers propose a novel system that uses standing surface acoustic waves to separate circulating tumor cells from red blood cells with unprecedented precision and efficiency. The platform ...

Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...

Madhya Pradesh has achieved 100 per cent target by screening 90,98,902 persons for the sickle cell disease so far, a ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

RBC Capital analyst Shelby Tucker maintained a Buy rating on PG&E (PCG – Research Report) on January 13 and set a price target of $24.00.

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

In a report released yesterday, Chris Dendrinos from RBC Capital maintained a Hold rating on Plug Power (PLUG – Research Report), with a price ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant funding from the National ...